中华消化杂志
中華消化雜誌
중화소화잡지
Chinese Journal of Digestion
2011年
3期
160-163
,共4页
谭红红%戈之铮%高云杰%陈慧敏%陈海英%房静远%刘文忠%萧树东
譚紅紅%戈之錚%高雲傑%陳慧敏%陳海英%房靜遠%劉文忠%蕭樹東
담홍홍%과지쟁%고운걸%진혜민%진해영%방정원%류문충%소수동
不明原因消化道出血%血管畸形%血管发育不良%低氧诱导因子-1%血管生成素-2
不明原因消化道齣血%血管畸形%血管髮育不良%低氧誘導因子-1%血管生成素-2
불명원인소화도출혈%혈관기형%혈관발육불량%저양유도인자-1%혈관생성소-2
Obscure gastrointestinal bleeding%Vascular malformation%Angiodysplasia%Hypoxia inducible factor -1%Angiopoietin-2
目的 探讨低氧诱导因子(HIF)-1及血管生成素(Ang)-2在血管畸形所致反复消化道出血中的表达及沙利度胺的干预作用.方法 筛选25例因反复消化道出血经胶囊内镜或小肠镜检查诊断为血管畸形者和18名无严重器质性疾病的正常对照者.另选取10例接受沙利度胺治疗(每日4次,每次25 mg,疗程4个月)并至少随访1年的血管畸形者.分别留取血标本,采用酶联免疫吸附试验(ELISA)检测血管畸形组与正常对照组以及沙利度胺治疗前后血清HIF-1及Ang-2的表达差异.结果 血管畸形组血清HIF-1及Ang-2表达量[分别为(113.84±26.66)和(652.11±140.39)ng/ml]均明显高于正常对照组[分别为(43.28±17.30)和(265.60±53.88)ng/ml,P值均=0.000],且二者表达显著相关(r=0.700,P=0.000).沙利度胺治疗前后HIF-1及Ang-2表达差异无统计学意义(P值分别=0.498和0.136).8例沙利度胺治疗有效者治疗后Ang-2表达量降低了(113.80±73.60)ng/ml(P=0.003).结论 HIF-1及Ang-2可能与血管畸形的形成有关,沙利度胺对血清Ang-2的抑制程度能预知其疗效或预后.
目的 探討低氧誘導因子(HIF)-1及血管生成素(Ang)-2在血管畸形所緻反複消化道齣血中的錶達及沙利度胺的榦預作用.方法 篩選25例因反複消化道齣血經膠囊內鏡或小腸鏡檢查診斷為血管畸形者和18名無嚴重器質性疾病的正常對照者.另選取10例接受沙利度胺治療(每日4次,每次25 mg,療程4箇月)併至少隨訪1年的血管畸形者.分彆留取血標本,採用酶聯免疫吸附試驗(ELISA)檢測血管畸形組與正常對照組以及沙利度胺治療前後血清HIF-1及Ang-2的錶達差異.結果 血管畸形組血清HIF-1及Ang-2錶達量[分彆為(113.84±26.66)和(652.11±140.39)ng/ml]均明顯高于正常對照組[分彆為(43.28±17.30)和(265.60±53.88)ng/ml,P值均=0.000],且二者錶達顯著相關(r=0.700,P=0.000).沙利度胺治療前後HIF-1及Ang-2錶達差異無統計學意義(P值分彆=0.498和0.136).8例沙利度胺治療有效者治療後Ang-2錶達量降低瞭(113.80±73.60)ng/ml(P=0.003).結論 HIF-1及Ang-2可能與血管畸形的形成有關,沙利度胺對血清Ang-2的抑製程度能預知其療效或預後.
목적 탐토저양유도인자(HIF)-1급혈관생성소(Ang)-2재혈관기형소치반복소화도출혈중적표체급사리도알적간예작용.방법 사선25례인반복소화도출혈경효낭내경혹소장경검사진단위혈관기형자화18명무엄중기질성질병적정상대조자.령선취10례접수사리도알치료(매일4차,매차25 mg,료정4개월)병지소수방1년적혈관기형자.분별류취혈표본,채용매련면역흡부시험(ELISA)검측혈관기형조여정상대조조이급사리도알치료전후혈청HIF-1급Ang-2적표체차이.결과 혈관기형조혈청HIF-1급Ang-2표체량[분별위(113.84±26.66)화(652.11±140.39)ng/ml]균명현고우정상대조조[분별위(43.28±17.30)화(265.60±53.88)ng/ml,P치균=0.000],차이자표체현저상관(r=0.700,P=0.000).사리도알치료전후HIF-1급Ang-2표체차이무통계학의의(P치분별=0.498화0.136).8례사리도알치료유효자치료후Ang-2표체량강저료(113.80±73.60)ng/ml(P=0.003).결론 HIF-1급Ang-2가능여혈관기형적형성유관,사리도알대혈청Ang-2적억제정도능예지기료효혹예후.
Objective To study the expressions of hypoxia inducible factor (HIF)-1 and angiopoietin (Ang)-2 in repeated gastrointestinal bleeding due to vascular malformation, and the efficacy of treatment with thalidomide. Methods Twenty-five patients with repeated gastrointestinal bleeding due to vascular malformation confirmed by capsule endoscopy or enteroscopy were collected and 18 subjects without severe diseases were served as controls. Ten patients with gastrointestinal vascular malformation, who received 25 mg of thalidomide 4 times daily for 4 months and were followed up for at least one year, were also enrolled. The serum samples from all participauts were detected for expressions of HIF-1 and Ang-2 using enzyme-linked immunosorbent assay (ELISA).The expressions of HIF-1 and Ang-2 were compared between angiodysplasia group and control group.The expressions of HIF-1 and Ang-2 were comparatively evaluated before and after treatment with thalidomide in treatment group. Results The expressions of HIF-1 and Ang-2 in vascular malformation group [( 113. 84 ± 26. 66 ) ng/ml and ( 652. 11 ± 140. 39) ng/ml, respectively] were significantly higher than that of control group [(43.28±17.30) ng/ml and (265.60±53.88) ng/ml,respectively, P=0. 000]. The expression of HIF-1 was positively associated with that of Ang-2. (r=0. 700, P= 0. 000). There was no difference in expressions of HIF-1 and Ang-2 before and after treatment with thalidomide (P=0. 498 and =0. 136, respectively). However, significant reduction of Ang-2 [(113. 80±73. 60) ng/ml(P=0. 003)] was found in 8 effectively treated patients after thalidomide treatment. Conclusions HIF-1 and Ang-2 might play an important role in the formation of vascular malformation. The extent of Ang-2 reduction after thalidomide treatment may be helpful in evaluating its efficacy or prognosis.
